$JUPW withdraws 10% of its outstanding shares to increase shareholder value: Jupiter Wellness, Inc. (NASDAQ: JUPW)
JUPW just acquired a $3 million business and initiated a $5 million stock buyback. JUPW has been featured on CNN, ABC, CBS, Bloomberg, Vogue and Forbes
– Developer of CBD-based treatments for multiple skincare applications.
– New e-commerce and marketing team with experienced industry veterans.
– JW-300 treatment Demonstrated effectiveness in developing burns (sunburn) in a clinical trial.
– Acquisition of Ascent Clinical Research adding $3 million in annual revenue plus contribution to EBITDA.
– Exclusive worldwide rights to patented anti-shark technologies.
– A new combined treatment with cannabidiol and aspartame significantly reduces the ISGA score in atopic dermatitis.
– Exclusive worldwide rights to unique formulas addressing Jellyfish and Man O’ War Stings, Sea Lice and Swimmer’s Itch with 4 patents pending.
– Clinical trial of JW-200 for the treatment of actinic keratosis.
– $5.0 million share buyback program.
JUPW announced the purchase and withdrawal of 2,433,894 common shares, reducing the number of outstanding common shares of the Company to 22,151,528, representing a reduction of approximately 10% of the outstanding shares.
The Company previously announced a $5.0 million share buyback program. Under this program, the Company’s shares may be repurchased periodically on the open market or in over-the-counter transactions. To date, the Company has purchased 2,433,894 under the program.
“We continue to believe that our shares are undervalued and today’s announcement demonstrates a continued commitment to our shareholders and a desire to retire shares at current market prices. Given our current cash position, I believe this program is an attractive use of capital as we continue to reposition ourselves for future growth,” said Brian John, CEO.
Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading developer of cannabidiol (CBD) therapeutic and medical wellness products. The JUPW clinical pipeline of prescription CBD-enhanced skin care therapeutics addresses indications such as eczema, burns, herpetic cold sores, and skin cancer. JUPW generates revenue from a growing line of exclusive over-the-counter skincare products, including its flagship CaniSun™ sunscreen and other wellness brands. JUPW has built a portfolio of award-winning wellness brands including CaniSun, fitCBD, Jack, Wellness CBD 1937, Black Belt CBD and Felix Ambrosia, as well as prescription therapeutics such as Photosil which have been featured in numerous media outlets including the Today Show, CNN, ABC, CBS, Animal Planet, AdWeek, Bloomberg, The Washington Post, Vogue, BuzzFeed and Forbes. As JUPW continues to expand portfolio of clinically tested, science-backed wellness, over-the-counter and prescription products, new marketing team poised to drive revenue
JUPW showcased its JW-300, a topical cannabidiol treatment for first-degree burns, at the SCALE 2022 Aesthetic Medicine, Plastic Surgery & Medical Dermatology conference held May 11-15, 2022 in Nashville.
The results demonstrate the potential of JW-300 as a prescription or over-the-counter topical cream to help prevent sunburn and its consequences, including skin cancer.
On April 27, JUPW announced that it had entered into an asset purchase agreement with Ascent Clinical Research, Inc. whereby it acquired certain clinical assets, including clinical trial research contracts worth $3 million. dollars in annual revenue for a purchase price of 5% future net revenue royalties. generated by assets. This asset purchase agreement adds immediate revenue to JUPW in Q2 2022 and positively contributes to EBITDA with no upfront payment or stock acquisition cost.
Watch the Discovery Channel videos on anti-shark technology here: https://youtu.be/Hqp04gdAXyk and here: https://youtu.be/PM0YTlbx1qg
On April 7, JUPW announced the upcoming launch of CaniSun for Shark Defense™, the latest addition to the company’s line of reef-friendly sunscreens. Through a licensing agreement with Shark Defense Technologies LLC, the leading researcher in chemical, electrochemical and magnetic shark repellents, JUPW owns the exclusive worldwide rights to the patents, formulas and production methods of the shark repellent technologies. for use in sunscreen and skin care products.
On April 6, JUPW announced the publication of the results of a clinical study to investigate the safety and efficacy of JW-100, its proprietary lotion formulation for the treatment of atopic dermatitis (eczema) in the Journal of Cosmetic. Dermatology, Vol. 21, number 4, April 2022, pages: 1647-1650.
On April 5, JUPW announced the launch of NoStingz, an exclusive line of sunscreens designed to protect against jellyfish and man-of-war stings, sea lice and swimmer’s itch while continuing to protect the skin. ocean lovers against UVA/UVB in a range of SPF. JUPW has signed a licensing agreement with Shark Defense Technologies for exclusive worldwide intellectual property rights to formulas and production methods for jellyfish protective compounds, including 4 patents pending. The agreement provides for future collaboration to develop and refine additional formulas.
To learn more about the JUPW NoStingz product or to purchase, visit: https://canisun.com/shop/nostingz-your-barrier-of-protection-from-sun-sea/
On February 18, JUPW announced that it had completed enrollment in its clinical trial of JW-200 for the treatment of actinic keratosis (AK), a common form of precancerous growths that typically appear as thick scaly lesions on the skin. exposed to the sun. If left untreated, up to 15.1% of patients with 10 or more AK lesions will develop keratinocyte carcinoma.
On January 25, JUPW announced that its board of directors had approved a $5.0 million stock repurchase program that expires on June 30, 2022. Under the stock repurchase program, common stock of JUPW may be repurchased periodically on the open market or in privately negotiated transactions.
For more information about Jupiter Wellness, Inc. (JUPW), visit www.jupiterwellnessinc.com. Where https://markets.financialcontent.com/streetinsider/article/getnews-2022-6-3-jupiter-wellness-jupw-to-offer-clinical-research-services-with-acquisition-of-ascent-clinical-research/
DISCLAIMER: Products mentioned are THC-free and/or Farm Bill 2018 compliant.
This article is for informational purposes only and does not constitute a recommendation to buy or sell stocks.
Company Name: Jupiter Wellness, Inc.
Contact person: Brian John, CEO
E-mail: Send an email
Call: 561 244 7100
Address:725 North Highway A1A, Suite C-106
State: FL 33477
Country: United States
Website: https://jupiterwellness.com/jupiter-wellness-inc-nasdaq-jupw-is-set-to-offer-clinical-research-services-with-the-3-million-dollar-acquisition-of-acquired-ascent- clinical research/